Comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies'.

Abstract

The <i>AIRE</i> gene plays a key role in the development of central immune tolerance by promoting thymic presentation of tissue-specific molecules. Patients with <i>AIRE</i>-deficiency develop multiple autoimmune manifestations and display autoantibodies against the affected tissues. In 2016 it was reported that: i) the spectrum of autoantibodies in patients with <i>AIRE</i>-deficiency is much broader than previously appreciated; ii) neutralizing autoantibodies to type I interferons (IFNs) could provide protection against type 1 diabetes in these patients (Meyer et al., 2016). We attempted to replicate these new findings using a similar experimental approach in an independent patient cohort, and found no evidence for either conclusion.